Effect of glucagon-like peptide-1 receptor agonists on major adverse cardiovascular events in adults with type 2 diabetes and established atherosclerotic cardiovascular disease: systematic review and meta-analysis of randomised trials.
Meta-analysis reveals reduced cardiovascular events and mortality in adults with type 2 diabetes and vascular disease, indicating robust protection across formulations.
Key Points
To assess the effect of GLP-1 receptor agonists, including recent trial evidence and oral formulations, on major adverse cardiovascular events in adults with type 2 diabetes and established atherosclerotic cardiovascular disease.
Conducted a systematic review and meta-analysis (PROSPERO CRD420251034652) following PRISMA 2020 guidelines, searching five databases through May 6, 2025.
Identified 7 randomized controlled trials involving 56,191 participants with a mean follow-up of 3.5 years comparing GLP-1 receptor agonists with placebo or usual care.
GLP-1 receptor agonists reduced major adverse cardiovascular events by 11% (HR: 0.89, 95% CI: 0.83–0.96) with high-certainty evidence.
All-cause mortality was reduced by 11% (HR: 0.89, 95% CI: 0.82–0.97) and hospitalization for heart failure was reduced by 7% (HR: 0.93, 95% CI: 0.89–0.98), both with high-certainty evidence.
Cite This Study
Montenegro-Avila et al. (2026) studied this question.